SCD5 and melanoma: In addition we observed a significant SCD5-dependent down-regulation of Preferentially Expressed Antigen in Melanoma (PRAME) (Figure 5B), a melanoma antigen causally implicated in tumor transformation and acting as a dominant inhibitor of the retinoic acid receptor (RAR) pathway [23].